This proposal requests continued support for the Medical Scientist Training Program (MSTP) at the Vanderbilt University School of Medicine. The primary goal of the Vanderbilt MSTP is to identify, mentor, and foster the careers of a diverse workforce of superior future leaders in academic medicine who are dedicated to improving human health through research, clinical activities, and leadership. Our joint MD/PhD program is based on rigorous training in clinical medicine and scientific inquiry. Core program elements developed specifically for dual-degree students include a foundational course in research, a literature-based seminar series, the Clinical Preceptorship Program, Data Club, leadership workshops, a career development workshop, the Physician- Scientist Speaker Series, extensive near-peer mentoring, and an annual retreat. Students receive formal instruction in responsible conduct of research and newly developed rigor and reproducibility throughout the curriculum. An innovative advising college program offers opportunities for vertical integration of faculty members, post-graduate physician-scientist trainees, and MSTP students. Current students hone their leadership skills by playing key roles in student recruitment, program administration, and curriculum development. 70% of our total graduates with established careers hold academic or private-sector research positions, including the founding president of Gladstone Institute, 3 deans, 3 department chairs, 26 full professors, and 18 industry leaders. More recent graduates still in training are in superb residencies and fellowships. The 103 current trainees come from 57 colleges and universities distributed across North America. Our increasing applicant pool results from concerted recruiting efforts, including those focused on the recruitment of students from groups underrepresented in medicine. In the current year, 475 applications have been received, from which 14 students will be selected to enter the incoming class. The educational environment for physician- scientists at Vanderbilt University is outstanding and currently Vanderbilt is ranked #8 in NIH funding. Building on established strengths in biomedical informatics, cancer biology, cell biology, clinical pharmacology, diabetes, neurosciences, toxicology, drug discovery, genetics, chemical and physical biology, imaging sciences, microbial pathogenesis, pharmacogenomics, and vaccine science. New areas of research emphasis include addiction, immunobiology, inflammation and cancer, precision medicine, stem cell biology, quantitative systems biology, and structural biology. We are building on this very solid foundation in increasing the size of the program to a steady state of 113 students over the next decade. Based on the commitment of our leadership team, the strength of our applicant pool, enhanced opportunities for physician-scientist training, a longstanding institutional commitment to the education of Vanderbilt MSTP leaders in biomedical research, and the success of our graduates in academic medicine, this proposal requests an increase in NIH-funded positions to 26 for the 5-year project period.

Public Health Relevance

The primary goal of the Vanderbilt MSTP is to identify, mentor, and train a diverse workforce of future leaders in academic medicine who are dedicated to improving human health through research, clinical activities, and leadership. The public health benefit is realized through the integrated clinical and research accomplishments of our graduates as they elucidate the basic mechanisms of disease and capitalize on these understandings in developing new therapeutic agents and strategies.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Institutional National Research Service Award (T32)
Project #
5T32GM007347-42
Application #
9967011
Study Section
NIGMS Initial Review Group (TWD)
Program Officer
Gindhart, Joseph G
Project Start
1977-07-01
Project End
2024-06-30
Budget Start
2020-07-01
Budget End
2021-06-30
Support Year
42
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Pediatrics
Type
Schools of Medicine
DUNS #
965717143
City
Nashville
State
TN
Country
United States
Zip Code
37203
McKenna, Matthew T; Weis, Jared A; Quaranta, Vito et al. (2018) Variable Cell Line Pharmacokinetics Contribute to Non-Linear Treatment Response in Heterogeneous Cell Populations. Ann Biomed Eng 46:899-911
Kozek, Krystian A; Du, Yu; Sharma, Swagat et al. (2018) Discovery and Characterization of VU0529331, a Synthetic Small-Molecule Activator of Homomeric G Protein-Gated, Inwardly Rectifying, Potassium (GIRK) Channels. ACS Chem Neurosci :
Sundermann, Alexandra C; Saum, Keith; Conrad, Kelsey A et al. (2018) Prognostic value of D-dimer and markers of coagulation for stratification of abdominal aortic aneurysm growth. Blood Adv 2:3088-3096
Athmer, Jeremiah; Fehr, Anthony R; Grunewald, Matthew E et al. (2018) Selective Packaging in Murine Coronavirus Promotes Virulence by Limiting Type I Interferon Responses. MBio 9:
Feng, QiPing; Wei, Wei-Qi; Chung, Cecilia P et al. (2018) Relationship between very low low-density lipoprotein cholesterol concentrations not due to statin therapy and risk of type 2 diabetes: A US-based cross-sectional observational study using electronic health records. PLoS Med 15:e1002642
Burns, Michael C; Howes, Jennifer E; Sun, Qi et al. (2018) High-throughput screening identifies small molecules that bind to the RAS:SOS:RAS complex and perturb RAS signaling. Anal Biochem 548:44-52
Zamora, Paula F; Hu, Liya; Knowlton, Jonathan J et al. (2018) Reovirus Nonstructural Protein ?NS Acts as an RNA Stability Factor Promoting Viral Genome Replication. J Virol 92:
Earl, David C; Ferrell Jr, P Brent; Leelatian, Nalin et al. (2018) Discovery of human cell selective effector molecules using single cell multiplexed activity metabolomics. Nat Commun 9:39
Hartmann, Katherine E; Velez Edwards, Digna R; Savitz, David A et al. (2018) THE AUTHORS REPLY. Am J Epidemiol 187:1133-1134
Trubiano, Jason A; Strautins, Kaija; Redwood, Alec J et al. (2018) The Combined Utility of Ex Vivo IFN-? Release Enzyme-Linked ImmunoSpot Assay and In Vivo Skin Testing in Patients with Antibiotic-Associated Severe Cutaneous Adverse Reactions. J Allergy Clin Immunol Pract 6:1287-1296.e1

Showing the most recent 10 out of 536 publications